Skip to main content
SpringerLink
Log in

Atezolizumab + nab-paclitaxel not cost effective in advanced PD-L1-positive triple-negative breast cancer

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chisaki Y, et al. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan. Clinical Drug Investigation : 5 Mar 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01017-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab + nab-paclitaxel not cost effective in advanced PD-L1-positive triple-negative breast cancer. PharmacoEcon Outcomes News 874, 7 (2021). https://doi.org/10.1007/s40274-021-7550-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7550-1

Search

Navigation